APEX1 and familial pancreatic carcinoma: Due to our published data demonstrating the synergistic effects of targeting the Ref‐1–STAT3 axis, we anticipated that APX3330 exposure would augment Rux‐mediated inhibition especially in models of pancreatic cancer that express high levels of Ref‐1 and STAT3.